A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Unknown 18 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.

Timeline

Start: 2016-05
Primary completion: 2017-12
Completion: 2018-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RUSERONTINIB	Small molecule	20 mg	Oral
Subject	RUSERONTINIB	Small molecule	200 mg	Oral

A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications